Despite the hype surrounding both companies and their products, there are significant risks involved. Novo's top-selling drugs carry health risks and their long-term benefits are uncertain. OpenAI's product, ChatGPT, has been criticized for its performance and has raised concerns about the future of AI. Both companies' high valuations are attributed more to what their products symbolize - control over our bodies and technology - rather than the products themselves.
Key takeaways:
- Novo Nordisk, a pharmaceutical company, is valued at around $506 billion following a successful year in sales of its semaglutide-based injectable drugs Ozempic and Wegovy, which is five times the estimated worth of OpenAI.
- OpenAI, the makers of ChatGPT, may soon reach a $100 billion valuation with the help of new investments, despite its value being difficult to determine due to it not being publicly traded.
- Both Novo Nordisk and OpenAI have seen significant growth and popularity in 2023, but their products carry risks and uncertainties, with Novo's drugs having potential health risks and OpenAI's technology not performing as well as expected.
- The high valuations of both companies are not solely based on their products, but on what they symbolize - the ability to control our bodies and the technology we interact with, which translates into significant financial value.